David A. Siegel Heron Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $47 Billion
- Q3 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Heron Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 182,071 shares of HRTX stock, worth $200,278. This represents 0.0% of its overall portfolio holdings.
Number of Shares
182,071
Previous 533,771
65.89%
Holding current value
$200,278
Previous $1.1 Million
78.89%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding HRTX
# of Institutions
188Shares Held
151MCall Options Held
20.1KPut Options Held
2.12M-
Rubric Capital Management LP New York, NY29.1MShares$32 Million0.61% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA10.2MShares$11.3 Million0.02% of portfolio
-
Clearline Capital LP New York, NY9.71MShares$10.7 Million0.62% of portfolio
-
Velan Capital Investment Management LP Alpharetta, GA8.75MShares$9.63 Million21.67% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.46MShares$9.31 Million0.0% of portfolio
About HERON THERAPEUTICS, INC.
- Ticker HRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 118,774,000
- Market Cap $131M
- Description
- Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single a...